Premium
Analysis of the REL , BCL11A , and MYCN proto‐oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia
Author(s) -
Deambrogi Clara,
De Paoli Lorenzo,
Fangazio Marco,
Cresta Stefania,
Rasi Silvia,
Spina Valeria,
Gattei Valter,
Gaidano Gianluca,
Rossi Davide
Publication year - 2010
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.21742
Subject(s) - chronic lymphocytic leukemia , amplicon , leukemia , medicine , oncology , cancer research , hematology , biology , genetics , gene , polymerase chain reaction
International audienceThe exact prevalence of gains of proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia (CLL) is currently unknown. We analysed the REL, BCL11A, and MYCN loci by FISH in a consecutive series of 176 newly diagnosed CLL. REL gain occurred in 3.4% cases, BCL11A gain in 2.8%, and MYCN gain in 2.3%. CLL harbouring MYCN gain showed an increased risk of death (HR:5.35; p=.006). By multivariate analysis, MYCN gain was an independent predictor of survival in CLL (HR:4.79; p=.017). Our observations indicate that: i) gains of REL, BCL11A and MYCN occur at a low frequency at CLL diagnosis; and ii) MYCN gain has potential prognostic relevance in CLL